Afatinib-d6 Dimaleate

Afatinib-d6 Dimaleate is a deuterated derivative of the drug Afatinib, which is used for the treatment of Non-Small Cell Lung Cancer. Afatinib-d6 Dimaleate is a kinase inhibitor that works by blocking the activity of certain proteins that promote the growth and spread of cancer cells. The deuterium substitution in Afatinib-d6 Dimaleate is an isotope of hydrogen that is used in the compound to enhance its pharmacokinetic properties, providing more stability and a longer half-life compared to the non-deuterated form. The chemical formula of Afatinib-d6 Dimaleate is C32H28D6N7O4S3.C4H4O4. The compound has a molecular weight of 857.03 g/mol. Afatinib-d6 Dimaleate is administered orally, usually in the form of tablets. The recommended dosage varies depending on the patient's condition and medical history. It is important to follow the prescribed dosage and treatment plan to ensure the best possible outcome. Like all drugs, Afatinib-d6 Dimaleate can cause side effects. The most common side effects include diarrhea, skin rash, and nail changes. More serious side effects, such as liver toxicity, may occur in rare cases. Patients should inform their doctor if they experience any side effects while taking Afatinib-d6 Dimaleate. In conclusion, Afatinib-d6 Dimaleate is an effective and widely used drug for the treatment of Non-Small Cell Lung Cancer. Its deuterium substitution provides greater stability and longer half-life compared to the non-deuterated form. However, patients should be aware of the potential side effects and follow their doctor's instructions closely.